Early Corticosteroids in Severe Influenza Pneumonia
Key facts
- Who runs it
- Centre Hospitalier Régional Metz-Thionville
- Where
- France48 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 544 people, planned
- Started
- Sept 2026
- Expected to end
- Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Dexametasone
- Sodium chloride 0.9% (placebo)
- Record updated
- 28 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age ≥ 18 y
- Admission to ICU or intermediate care for less than 2 days
- Admission to hospital for less than 5 days
- Diagnosis of influenza pneumonia with; PCR positive for Influenza dated less than 5 days; AND focal shadowing/infiltrates on chest X-ray or CT-scan; AND at least one of the following: cough, purulent sputum, chest pain or dyspnoea
- Requirement of supplemental oxygen at a flow rate of at least 3L/min OR non-invasive ventilation OR high flow oxygen therapy OR invasive mechanical ventilation
- Written informed or emergency consent
- Ongoing medical insurance
Who cannot take part
- Bone marrow transplant or chemotherapy-induced neutropenia
- Subject with shock on enrolment and on ongoing vasopressor therapy (≥ 0.25 microg/kg/min)
- Indication for corticosteroid therapy in a dosage above 0.5mg/kg/day prednisone-equivalent
- Known allergy to dexamethasone or to one of its excipients
- Co-infection with COVID-19
- Known active tuberculosis or fungal infection
- Active viral hepatitis or active herpes virus infection
- Moribund state
- Uncontrolled psychotic states
- Pheochromocytoma
- Cardiogenic shock secondary to influenza myocarditis
- Patient at risk of strongyloidiasis
- Subject deprived of liberty or under a legal protective measure (example: patients under guardianship or curatorship)
- Pregnant or breastfeeding woman
- Lack of clinical equipoise by the attending physician and/or the presence of a substantial risk associated with the patients' participation in the trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Phase III, multicentre, randomized, controlled, double-blind, superiority trial aiming to evaluate the efficacy of dexamethasone versus placebo in patients admitted to intensive care or intermediate care with influenza and hypoxemic acute respiratory failure. Patients will receive state-of-the-art standard therapy for severe influenza. They will be randomized in a 1:1 ratio to one of the two arms. Patients, investigators and care providers will be blinded to the patient arm. Patients will receive antiviral treatment and antibiotic therapy if bacterial co-infection is suspected. All clinical interventions such as use of ventilatory strategy, laboratory tests, and hemodynamic management will be left at the discretion of the team in both arms. Special attention will be given to the prompt diagnosis and management of aspergillosis, with investigators provided with decision support tools and algorithms based on the most recent definition (i.e., FUNDICU). Patients will be followed for up to 28 days after enrolment and national registries will be used for 90-day vital status assessment. Telephone calls will be made on day 90 to assess quality of life.
The 2 groups in the trial
- DexamethasoneTreatment being tested
a daily dose of 6 mg dexamethasone (investigational medicinal product) suspended in sodium chloride 0.9% and administered as a masked intravenous injection (total volume of 5 ml) once daily for up to 10 days from randomization OR until discharge from the participating intensive care or intermediate care unit.
Treatment: Dexametasone
- PlaceboPlacebo, for comparison
a daily dose of placebo (sodium chloride 0.9%, total volume of 5 ml) intravenously once daily for up to 10 days from randomization OR until discharge from the participating intensive care or intermediate care unit.
Treatment: Sodium chloride 0.9% (placebo)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Early Corticosteroids in Severe Influenza Pneumonia, a Phase III Randomized Controlled Trial
- Record updated
- 28 August 2026